Nav: Home

Induced labor at 39 weeks reduces cesarean births

August 08, 2018

  • Elective induction at 39 weeks reduces maternal and newborn complications
  • Newborns have fewer respiratory problems
  • Women report less labor pain, have lower rates of preeclampsia and gestational hypertension
  • Study involved more than 6,100 women
CHICAGO --- For many years, obstetricians counseled women that inducing labor increased the likelihood of a cesarean birth, although there was no solid evidence in clinical trials to support that.

Now, a large national study led by a Northwestern Medicine investigator shows electively inducing labor at 39 weeks actually reduces the rate of cesarean deliveries and decreases maternal and fetal complications.

In the study, women who were assigned to the elective induction group also reported experiencing less pain in labor and a greater sense of control over the labor process than women who were not in the induction group.

The paper will be published Aug. 9 in the New England Journal of Medicine.

"There's a lot of controversy around the consequences of inducing labor. People were convinced that it increased the risk of cesarean delivery, but the reality was actually unknown," said Dr. William Grobman, the Arthur Hale Curtis Professor of Obstetrics and Gynecology at Northwestern University Feinberg School of Medicine and a Northwestern Medicine physician. "This study provides evidence that inducing labor at 39 weeks actually reduces cesarean delivery."

In the U.S., approximately one-third of women give birth via cesarean delivery, which is associated with an increased risk of infection, hysterectomy, placenta implantation abnormalities in future pregnancies and respiratory illness in infants.

In the study, more than 6,100 women from 41 sites around the country were divided into two groups: one that waited for labor to begin on its own and one that would undergo an elective induction at 39 weeks of gestation.

The investigators chose 39 weeks because that is when babies have reached full term and have a low frequency of neonatal complications.

Among the key results:
  • Lower rates of cesarean delivery among the elective induction group (19 percent) compared to non-induction group (22 percent)
  • Lower rates of preeclampsia and gestational hypertension group (9 percent) compared to the non-induction group (14 percent)
  • Lower rates of respiratory support among newborns in the induction group (3 percent) compared to the non-induction group (4 percent)
The study's data suggest that one cesarean delivery may be avoided for every 28 deliveries among low-risk women giving birth for the first time who plan to undergo elective induction of labor at 39 weeks.

In addition to this large trial, a recent smaller study in Britain found that induction of labor also did not result in an increase of cesarean delivery.

"This new knowledge gives women the autonomy and ability to make more informed choices regarding their pregnancy that better fit with their wishes and beliefs," Grobman said. "Induction at 39 weeks should not be routine for every woman, but it's important to talk with their provider and decide if they want to be induced and when."
-end-
The paper is titled, "Labor Induction versus Expectant Management in Low-Risk Nulliparous Women."

The study was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health, grant NCT01990612.

Northwestern University

Related Clinical Trials Articles:

Giving children a voice in clinical trials
Children as young as 8 years old with incurable cancer can reliably characterize the impact an experimental therapy has on their symptoms and quality of life -- even at the earliest stages of drug development -- making self-reported patient outcomes a potential new clinical trial endpoint.
Better health for women involved in clinical trials
Women who participate in obstetric and gynecology clinical trials experience improved health outcomes compared to those who are not involved in trials, according to research by Queen Mary University of London.
Final artificial pancreas clinical trials now open
Clinical trials are now enrolling to provide the final tests for a University of Virginia-developed artificial pancreas to automatically monitor and regulate blood-sugar levels in people with type 1 diabetes.
Why the bar needs to be raised for human clinical trials
Standards for authorizing first-time trials of drugs in humans are lax, and should be strengthened in several ways, McGill University researchers argue in a paper published today in Nature.
New drug formulary will help expedite use of agents in clinical trials
The National Cancer Institute (NCI) today launched a new drug formulary (the 'NCI Formulary') that will enable investigators at NCI-designated Cancer Centers to have quicker access to approved and investigational agents for use in preclinical studies and cancer clinical trials.
More Clinical Trials News and Clinical Trials Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...